Strong and Moderate CYP3A Inducers
Concomitant use of selpercatinib with a strong or moderate CYP3A inducer decreases pemigatinib plasma concentrations, which may reduce the efficacy of selpercatinib. Avoid concomitant use of strong and moderate CYP3A inducers with
selpercatinib.
Strong and Moderate CYP3A Inhibitors
Concomitant use of a strong or moderate CYP3A inhibitor with selpercatinib increases pemigatinib plasma concentrations, which may increase the incidence and severity of adverse reactions. Avoid concomitant use of strong and moderate CYP3A inhibitors with selpercatinib. Reduce selpercatinib dosage if concomitant use of strong and moderate CYP3A inhibitors cannot be avoided.
from FDA,2024.06
Selpercatinib is a targeted therapy drug specifically designed to fight various ···【more】
Release date:2024-08-19Recommended:160
Selpercatinib is a drug that targets mutations in the RET gene and is suitable f···【more】
Release date:2024-08-19Recommended:121
In 2020, Selpercatinib was approved by the FDA as the first highly selective RET···【more】
Release date:2024-08-19Recommended:138